PDS Biotechnology Corporation (PDSB)
Stock Price:
$1.67 USD
-0.05 (-2.91%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
25.65M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.80M |
| Shares Out |
15.36M |
| EPS (ttm) |
-2.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$1.67 |
| Previous Close |
$1.72 |
| Change ($) |
-0.05 |
| Change (%) |
-2.91% |
| Day's Open |
1.78 |
| Day's Range |
1.64 - 1.78 |
| Day's Volume |
590,425 |
| 52-Week Range |
0.62 - 6.71 |
More Stats
| Market Cap |
25.65M |
| Enterprise Value |
4.62M |
| Earnings Date (est) |
Jul 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.36M |
| Float |
10.75M |
| EPS (basic) |
-3.08 |
| EPS (diluted) |
-2.74 |
| FCF / Share |
-1.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
36,313 |
| Short Ratio |
0.04 |
| Short % of Float |
0.30% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.12 |
| Revenue |
n/a |
| Operating Income |
-20.13M |
| Net Income |
-17.80M |
| Free Cash Flow |
-17.60M |
| Net Cash |
21.04M |
| Net Cash / Share |
1.37 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-36.78% |
| ROE |
-80.30% |
| ROIC |
1,558.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.72*
(182.63% upside)
Low
4.00
Current: 1.67
High
5.45
Target: 4.72
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -21.03 | -3.65 | -51.97 | -39.51 | -26.50 | -13.19 | -6.49 |
| Net Income | -7.00 | -3.84 | -50.86 | -38.82 | -28.08 | -12.20 | -6.88 |
| Shares Outstanding | 4.87 | 3.34 | 1.52 | 1.44 | 0.40 | 0.08 | 0.08 |
| Earnings Per Share | -1.44 | -1.15 | -33.40 | -26.80 | -80.20 | -163.20 | -94.20 |
| Operating Cash Flow | -18.07 | -1.57 | -40.70 | -32.19 | -21.75 | -9.72 | -8.04 |
| Capital Expenditures | 0.28 | - | -0.19 | -0.69 | -1.31 | -0.88 | -0.14 |
| Free Cash Flow | -17.80 | -1.57 | -40.89 | -32.88 | -23.06 | -10.60 | -8.18 |
| Cash & Equivalents | 12.16 | 0.10 | 88.07 | 106 | 130 | 13.73 | 7.86 |
| Total Debt | - | 0.03 | 20.46 | 14.95 | 5.30 | 2.59 | - |
| Net Cash / Debt | 12.16 | 0.07 | 67.61 | 91.45 | 125 | 11.14 | 7.86 |
| Assets | 14.49 | 0.16 | 92.62 | 111 | 134 | 16.85 | 8.73 |
| Liabilities | 2.79 | 2.23 | 30.25 | 21.64 | 11.62 | 44.68 | 24.08 |
| Book Value | 11.70 | -2.07 | 62.37 | 89.28 | 122 | -27.83 | -15.35 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
PDS Biotechnology Corporation |
| Country |
United States |
| Employees |
16 |
| CEO |
Frank K. Bedu-Addo |
Stock Information
| Ticker Symbol |
PDSB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PDSB |
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.